Ascension Wisconsin recently honored Racine paramedics and the Ascension All Saints Hospital Emergency Department for their ...

The FDA approved tenecteplase (TNKase) for adult stroke patients, Genentech announced on Monday. A clot-dissolving tissue ...

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the ...

The approval was supported by data from the registry-linked, parallel group, open-label, randomized AcT trial, which compared tenecteplase to alteplase.

The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.